Pfizer (PFE) is scheduled to report the results of its third fiscal quarter before the market open on October 30, with a conference call scheduled for 10:00 am EDT. What to watch for: 1. 2018 GUIDANCE: Along with its second quarter financial report in late July, the drug giant gave its view for FY18. Pfizer raised its FY18 adjusted EPS view to $2.95-$3.05 from $2.90-$3.00 on a lowered revenue view of $53B-$55B, down from its previous view of $53.5B-$55.5B. Analysts are currently expecting FY18 EPS of $2.99 on revenue of $54.15B. Pfizer said Innovative Health revenues increased 5% operationally in second-quarter 2018, primarily driven by continued growth from key brands including Eliquis, Ibrance and Xeljanz globally, Prevnar 13/Prevenar 13 primarily in emerging markets and the U.S., as well as Xtandi in the U.S. Operational revenue growth for Eliquis, Ibrance, Xeljanz and Xtandi was 42%, 19%, 37% and 21%, respectively. Second quarter IH operational revenue growth was negatively impacted primarily by the loss of exclusivity of Viagra in the U.S. in December 2017. REACTION TO TRUMP TWEET: According to a CNBC interview, after President Donald Trump publicly condemned Pfizer for raising the price of about 40 drugs, Pfizer CEO Ian Read said he knew the best move would be to defer its early July price increases. “After he tweeted, we looked at the various situations, and we decided before I spoke to him we needed to defer the price increases,” Read said in a telephone interview in July with CNBC. Why? “Because we wanted to have a positive relationship with the Hill and administration as we go through this blueprint.” 3. MORE BLOCKBUSTERS IN PIPELINE: According to reports, Pfizer is looking to increase research and development spending and pay more attention to smaller deals as the drug giant aims to accelerate the delivery of potential blockbuster treatments to market. “We now believe we are getting close to a growth period,” Ian Read said in an interview after its last quarterly report. After dropping plans to do a mega deal, Pfizer is increasing its R&D efforts as it anticipates 25 to 30 drugs from its pipeline to be approved through 2022, according to a Wall Street Journal interview this past summer. 4. TANEZUMAB SUCCESS: Pfizer and Eli Lilly and Company (LLY) announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab were associated with a statistically significant improvement in pain, physical function and patient’s global assessment of their OA, compared to placebo.